Skip to content
value.today

NextPoint Therapeutics, Inc.

Total raised
$156 M
3 rounds on record
Latest round
$34 M
Jul 2026
First round on record
Dec 2022
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of NextPoint Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2026$34 MNo. 3$10 to $50 million

NextPoint Therapeutics, Inc.: Raise no. 3, Jul 2026

Investors in this round

15 investors had bought by the notice of Jul 30, 2026: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$34 M of $49 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$2,548,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ivan Cheung · Executive Officer, Director
  • Jeffrey Lacey · Executive Officer
  • Axel Hoos · Director
  • Brian Shuster · Director
  • Detlev Biniszkiewicz · Director
  • Paulina Hill · Director
  • R. Jacob Vogelstein · Director
  • Rakhshita Dhar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Lacey, Secretary & Treasurer. Source: SEC Form D, newest notice filed Jul 30, 2026. Read the notice at the SEC.

equity, optionsSEC
Jan 2024$42 MNo. 2$10 to $50 million

NextPoint Therapeutics, Inc.: Raise no. 2, Jan 2024

Investors in this round

15 investors had bought by the notice of Feb 14, 2024: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$42 M of $42 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ivan Cheung · Executive Officer, Director
  • Paul Conrad · Executive Officer
  • Axel Hoos · Director
  • Detlev Biniszkiewicz · Director
  • Matthew Roden) · Director
  • Paulina Hill · Director
  • R. Jacob Vogelstein · Director
  • Rakhshita Dhar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Conrad, Secretary and Treasurer. Source: SEC Form D, newest notice filed Feb 14, 2024. Read the notice at the SEC.

equitySEC
Dec 2022$80 MNo. 1$50 to $250 million

NextPoint Therapeutics, Inc.: Raise no. 1, Dec 2022

Investors in this round

13 investors had bought by the notice of Dec 27, 2022: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,700,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Detlev Biniszkiewicz · Executive Officer, Director
  • Paul Conrad · Executive Officer
  • Ansbert Gadicke · Director
  • Matthew Roden · Director
  • Paulina Hill · Director
  • Rakhshita Dhar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Conrad, Secretary and Treasurer. Source: SEC Form D, newest notice filed Dec 27, 2022. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NextPoint Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2026).

    SEC Form D · Jul 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2026

That is all the official record says: NextPoint Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of NextPoint Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NextPoint Therapeutics, Inc.
NameRoleNamed in
Ivan CheungExecutive officerJul 2026
Jeffrey LaceyExecutive officerJul 2026
Paul ConradExecutive officerFeb 2024
Detlev BiniszkiewiczExecutive officerDec 2022
Axel HoosDirectorJul 2026
Brian ShusterDirectorJul 2026
Detlev BiniszkiewiczDirectorJul 2026
Ivan CheungDirectorJul 2026
Paulina HillDirectorJul 2026
R. Jacob VogelsteinDirectorJul 2026
Rakhshita DharDirectorJul 2026
Matthew Roden)DirectorFeb 2024
Ansbert GadickeDirectorDec 2022
Matthew RodenDirectorDec 2022